(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
4 December 2008 (04.12.2008)

PCT

(10) International Publication Number
WO 2008/147314 A1

(51) International Patent Classification:
C07D 405/04 (2006.01) *C07D 401/04* (2006.01)
A61K 31/438 (2006.01) *C07D 405/12* (2006.01)
A61K 31/444 (2006.01) *C07D 405/14* (2006.01)
A61K 31/4545 (2006.01) *C07D 409/04* (2006.01)
C07D 221/20 (2006.01)

(21) International Application Number:
PCT/SE2008/050606

(22) International Filing Date: 23 May 2008 (23.05.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/940,350 25 May 2007 (25.05.2007) US

(71) Applicant *(for all designated States except US)*: **ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **BERNSTEIN, Peter** [US/US]; AstraZeneca Wilmington, 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US). **BROWN, Dean** [US/US]; AstraZeneca Wilmington, 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US). **CACCIOLA, Joseph** [US/US]; AstraZeneca Wilmington, 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US). **EDWARDS, Phil** [US/US]; AstraZeneca Wilmington, 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US). **FOLMER, James** [US/US]; AstraZeneca Wilmington, 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US). **GROBLEWSKI, Thierry** [FR/CA]; AstraZeneca R & D Montreal, 7171 Frederick-Banting, Ville St. Laurent, Montreal, Québec H4S 1Z9 (CA). **SYLVESTER, Mark** [US/US]; AstraZeneca Wilmington, 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US). **WESOLOWSKI, Steven** [US/US]; AstraZeneca Wilmington, 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US).


(74) Agent: **ASTRAZENECA AB**; AstraZeneca Intellectual Property, S-151 85 Södertälje (SE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

(54) Title: SPIROCYCLOPROPYL PIPERIDINE DERIVATIVES



(I)

(57) Abstract: Disclosed herein is at least one piperidine derivative, at least one pharmaceutical composition comprising at least one piperidine derivative disclosed herein for treating at least one histamine H3 receptor associated condition therewith

WO 2008/147314 A1